交易 Marker Therapeutics, Inc. - MRKR CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Marker Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|
Marker Therapeutics, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Tuesday, June 6, 2023 | ||
时间(协调世界时) (UTC) 13:00 | 国家/地区 US
| 事件 Marker Therapeutics Inc Annual Shareholders Meeting Marker Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 9, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q2 2023 Marker Therapeutics Inc Earnings Release Q2 2023 Marker Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 8, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q3 2023 Marker Therapeutics Inc Earnings Release Q3 2023 Marker Therapeutics Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 9.01354 | 1.24171 | 0.46679 | 0.21319 | 0.20599 |
总营业费用 | 39.1923 | 43.1263 | 29.3526 | 22.742 | 148.378 |
销售/一般/行政费用,总计 | 12.82 | 12.9248 | 10.4719 | 9.9772 | 24.3799 |
研究与开发 | 26.1393 | 27.7949 | 18.8808 | 12.7648 | 123.998 |
异常费用(收入) | 0.23297 | 2.40658 | 0 | ||
营业收入 | -30.1788 | -41.8846 | -28.8858 | -22.5288 | -148.172 |
利息收入(费用),非经营净值 | 0.24806 | 0.0057 | 0.17974 | 1.10084 | 0.21372 |
其他,净值 | |||||
税前净收入 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
税后净收入 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
未计算非常项目前的净收益 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
净收入 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
普通股股东可获收益 (不含非经常性项目) | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
普通股股东可获收益 (含非經常性項目) | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
摊薄净收入 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
摊薄后加权平均股 | 8.351 | 7.65057 | 4.70399 | 4.55877 | 1.90919 |
扣除特别项目的每股摊薄盈利 | -3.58408 | -5.47396 | -6.1025 | -4.70038 | -77.4976 |
每股正常摊薄盈利 | -3.55619 | -5.15939 | -6.1025 | -4.70038 | -77.4976 |
收入 | 9.01354 | 1.24171 | 0.46679 | 0.21319 | 0.20599 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 4.73434 | 3.30914 | 3.94957 | 0.79051 | 0.96432 |
总营业费用 | 9.78657 | 7.27497 | 10.9689 | 10.0705 | 10.8779 |
销售/一般/行政费用,总计 | 2.51582 | 1.89382 | 3.67801 | 3.51518 | 3.733 |
研究与开发 | 7.27074 | 5.26706 | 7.2909 | 6.5553 | 7.02607 |
营业收入 | -5.05223 | -3.96583 | -7.01933 | -9.27997 | -9.91363 |
利息收入(费用),非经营净值 | 0.08465 | 0.10941 | 0.09975 | 0.03579 | 0.00312 |
税前净收入 | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
税后净收入 | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
未计算非常项目前的净收益 | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
净收入 | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
普通股股东可获收益 (不含非经常性项目) | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
普通股股东可获收益 (含非經常性項目) | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
摊薄净收入 | -4.96758 | -3.85642 | -6.91958 | -9.24419 | -9.91051 |
摊薄后加权平均股 | 8.72103 | 8.37358 | 8.35992 | 8.3592 | 8.31076 |
扣除特别项目的每股摊薄盈利 | -0.56961 | -0.46055 | -0.82771 | -1.10587 | -1.19249 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.56961 | -0.44692 | -0.82771 | -1.10587 | -1.17819 |
收入 | 4.73434 | 3.30914 | 3.94957 | 0.79051 | 0.96432 |
异常费用(收入) | 0 | 0.11409 | 0 | 0 | 0.11888 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 16.6193 | 45.9822 | 24.4109 | 45.4866 | 61.9966 |
现金和短期投资 | 11.7822 | 42.3512 | 21.3524 | 43.9039 | 61.7467 |
现金等价物 | 11.7822 | 42.3512 | 21.3524 | 43.9039 | 61.7467 |
Prepaid Expenses | 2.43508 | 2.48463 | 2.05792 | 1.52644 | 0.14172 |
Total Assets | 34.4222 | 68.1351 | 45.6148 | 46.3593 | 62.1443 |
Total Current Liabilities | 7.78181 | 12.9016 | 6.4018 | 1.99281 | 2.80357 |
Payable/Accrued | 0.75561 | 3.04191 | 0.40401 | 0.44168 | 0.71957 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.5 | 1.14619 | 0 | 0.031 | 0.049 |
Total Liabilities | 14.8211 | 24.1495 | 18.2702 | 2.27306 | 2.80357 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 19.601 | 43.9856 | 27.3446 | 44.0862 | 59.3407 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.00841 | 0.08308 | 0.05073 | 0.04573 | 0.04544 |
Additional Paid-In Capital | 447.642 | 442.021 | 383.533 | 371.574 | 365.401 |
Retained Earnings (Accumulated Deficit) | -428.049 | -398.118 | -356.239 | -327.533 | -306.105 |
Total Liabilities & Shareholders’ Equity | 34.4222 | 68.1351 | 45.6148 | 46.3593 | 62.1443 |
Total Common Shares Outstanding | 8.4 | 8.31 | 5.07 | 4.57 | 4.54 |
应收账款总额,净额 | 2.402 | 0.00024 | 1 | 0.05619 | 0.10818 |
Property/Plant/Equipment, Total - Net | 17.8029 | 22.1529 | 21.204 | 0.8727 | 0.14767 |
Property/Plant/Equipment, Total - Gross | 23.0768 | 24.8931 | 21.7952 | 0.97817 | 0.14767 |
Accumulated Depreciation, Total | -5.27386 | -2.74014 | -0.59126 | -0.10547 | 0 |
Accounts Payable | 1.612 | 5.144 | 2.935 | 0.993 | 1.619 |
Accrued Expenses | 2.9142 | 3.56949 | 3.06279 | 0.52713 | 0.416 |
Other Liabilities, Total | 7.03934 | 11.2479 | 11.8684 | 0.28025 | |
Other Current Assets, Total | 0 | 1.14619 | 0.00056 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 10.9129 | 16.6193 | 22.4231 | 29.276 | 31.0175 |
现金和短期投资 | 6.40124 | 11.7822 | 18.0764 | 25.8217 | 28.6372 |
现金等价物 | 6.40124 | 11.7822 | 18.0764 | 25.8217 | 28.6372 |
应收账款总额,净额 | 2.08289 | 2.402 | 1.68102 | 0.62763 | 0.00219 |
Prepaid Expenses | 2.42874 | 2.43508 | 2.66567 | 2.8267 | 2.19623 |
Total Assets | 27.941 | 34.4222 | 41.1146 | 52.3197 | 54.9561 |
Property/Plant/Equipment, Total - Net | 17.0282 | 17.8029 | 18.6915 | 23.0437 | 23.9386 |
Property/Plant/Equipment, Total - Gross | 23.1203 | 23.0768 | 23.3627 | 26.9395 | 27.2547 |
Accumulated Depreciation, Total | -6.09209 | -5.27386 | -4.67118 | -3.89584 | -3.31606 |
Total Current Liabilities | 5.20405 | 7.78181 | 11.2868 | 13.4736 | 8.21451 |
Accounts Payable | 2.863 | 1.612 | 2.021 | 1.767 | 5.016 |
Payable/Accrued | 0.62397 | 0.75561 | 0.7174 | 0.66225 | 0.74068 |
Accrued Expenses | 1.71708 | 2.9142 | 3.49845 | 3.04439 | 2.27597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12.0277 | 14.8211 | 18.5128 | 24.2935 | 19.2504 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 6.82365 | 7.03934 | 7.22599 | 10.8198 | 11.0359 |
Total Equity | 15.9134 | 19.601 | 22.6017 | 28.0263 | 35.7058 |
Common Stock | 0.0088 | 0.00841 | 0.0836 | 0.0836 | 0.08345 |
Additional Paid-In Capital | 448.921 | 447.642 | 446.711 | 445.216 | 443.651 |
Retained Earnings (Accumulated Deficit) | -433.017 | -428.049 | -424.193 | -417.273 | -408.029 |
Total Liabilities & Shareholders’ Equity | 27.941 | 34.4222 | 41.1146 | 52.3197 | 54.9561 |
Total Common Shares Outstanding | 8.8 | 8.4 | 8.36 | 8.36 | 8.35 |
Other Current Assets, Total | 0 | 0 | 0 | 0.18186 | |
Other Current Liabilities, Total | 0 | 2.5 | 5.05 | 8 | 0.18186 |
Accounts Receivable - Trade, Net | 1 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -29.9307 | -41.8789 | -28.7061 | -21.428 | -147.958 |
经营活动产生的现金 | -26.9722 | -27.2798 | -20.0347 | -18.2843 | -14.4799 |
非现金物品 | 5.98266 | 6.9777 | 5.78745 | 5.52043 | 132.435 |
Cash Taxes Paid | |||||
已付现金利息 | |||||
营运资金的变化 | -5.81323 | 5.47242 | 2.39829 | -2.48188 | 1.04252 |
融资活动产生的现金 | 0.20213 | 52.5559 | 6.73601 | 0.81648 | 71.245 |
融资现金流项目 | |||||
股票的发行(报废),净额 | 0.20213 | 52.5559 | 6.73601 | 0.81648 | 71.245 |
债务的发行(退还),净额 | |||||
现金净变化 | -31.7152 | 22.145 | -22.5516 | -17.8428 | 56.6175 |
投资活动产生的现金 | -4.94514 | -3.13113 | -9.25289 | -0.37498 | -0.14767 |
资本支出 | -4.94514 | -3.13113 | -9.25289 | -0.37498 | -0.14767 |
经营活动产生的现金 | 2.78911 | 2.14898 | 0.48564 | 0.10512 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.96758 | -29.9307 | -26.0743 | -19.1547 | -9.91051 |
Cash From Operating Activities | -5.8883 | -26.9722 | -20.6667 | -13.0208 | -12.2261 |
Cash From Operating Activities | 0.81822 | 2.78911 | 1.976 | 1.15611 | 0.57633 |
Non-Cash Items | 0.81343 | 5.98266 | 5.11359 | 3.64886 | 1.88857 |
Changes in Working Capital | -2.55237 | -5.81323 | -1.68204 | 1.32896 | -4.78045 |
Cash From Investing Activities | -0.11261 | -4.94514 | -4.81779 | -4.71843 | -2.45219 |
Capital Expenditures | -0.11261 | -4.94514 | -4.81779 | -4.71843 | -2.45219 |
Cash From Financing Activities | 0.61997 | 0.20213 | 0.06357 | 0.06357 | 0 |
Issuance (Retirement) of Stock, Net | 0.61997 | 0.20213 | 0.06357 | 0.06357 | 0 |
Net Change in Cash | -5.38093 | -31.7152 | -25.4209 | -17.6756 | -14.6783 |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Marker Therapeutics, Inc. Company profile
关于 Marker Therapeutics Inc.
Marker Therapeutics, Inc.是一家处于临床阶段的免疫肿瘤学公司。 该公司专门从事基于T细胞的免疫疗法和基于肽的疫苗的开发和商业化,用于治疗血液恶性肿瘤和实体肿瘤的适应症。 公司从其MultiTAA特异性T细胞技术中开发出了领先的候选产品,该技术基于非工程化的肿瘤特异性T细胞的选择性扩增,这些T细胞能够识别肿瘤相关抗原(TAAs),这些抗原是肿瘤靶点,然后杀死表达这些靶点的肿瘤细胞。 该公司有三种MultiTAA特异性T细胞疗法通过临床开发,其中包括自体MultiTAA特异性T细胞疗法,异体MultiTAA特异性T细胞疗法和现成的MultiTAA特异性T细胞疗法。 公司专注于开发MT-601,用于治疗晚期不可切除的胰腺癌。
Industry: | Biotechnology & Medical Research (NEC) |
4551 Kennedy Commerce Dr.
HOUSTON
TEXAS 77032
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。